More than half of patients with polymyalgia rheumatica have a relapse during tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 blockade may be clinically useful in ...

Please provide your email address to receive an email when new articles are posted on . Patients were more likely to achieve sustained remission with sarilumab vs. placebo. The most common adverse ...

For patients with polymyalgia rheumatica with relapse during tapering of glucocorticoid therapy, treatment with sarilumab, the human monoclonal antibody that binds to the interleukin-6 receptor α, is ...

Patients should be monitored for evidence of relapse, for disease-related complications, for steroid-related complications and for symptoms that may suggest an alternative diagnosis. In addition to ...

This article was originally published by HCPLive. In patients with polymyalgia rheumatica who relapsed while tapering prednisone, those receiving sarilumab were significantly more likely to achieve ...

We still do not know why there is vascular involvement in GCA as opposed to pure PMR. One of the major determinants of vascular involvement may be that CD4 + T cells do not secrete IFN-γ in PMR. DCs ...

However, patient-reported scores were not significantly better in the tocilizumab group. Tocilizumab (Actemra) appears to lead to meaningful results in patients with active polymyalgia rheumatica ...